Feature NeuroproteXeon targets Q2 start of Phase 3 Xenex trial By Len Zehr Closely-held NeuroproteXeon has received agreement on a special protocol assessment from the FDA for a Phase 3 trial of its inhaled pharmaceutical grade product, XENEX, a xenon gas formulation, as a... November 1, 2016